Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Medra

Explore full profile

AI-powered robotic platform automating laboratory experimentation

San Francisco, United StatesFounded 2021Biotech & Life Sciences
Valuation $250–500M Last recorded · 2025
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Medra and the history behind them.

About Medra

Medra is a San Francisco-based company developing a platform to accelerate scientific research by automating laboratory tasks through artificial intelligence and robotics. The company was founded by Michelle Lee, who serves as CEO. Lee holds a PhD from the Stanford AI Lab and was slated to become an assistant professor at New York University before leaving academia to establish Medra. Her background includes work at NVIDIA, SpaceX, and McKinsey. The founding team includes engineers with experience from companies like Tesla, SpaceX, and Neuralink.

Medra's core offering is its Continuous Science Platform, a system that integrates robotics and AI to manage and execute laboratory experiments. The platform consists of two main components: "Physical AI" and "Scientific AI". The Physical AI component uses general-purpose robotic systems to physically perform tasks, such as pipetting and handling biological samples, interfacing with standard lab instruments. This system is designed for flexibility, allowing scientists to adapt workflows using natural language instructions. The Scientific AI component then interprets the data and results from these experiments, identifies patterns, and suggests improvements or new experimental paths, creating a continuous, closed-loop learning system. This integration aims to solve the bottleneck of data scarcity in scientific research by enabling experiments to be run at a much larger scale and faster pace than is possible manually.

The company's business model involves deploying its systems to clients and is also planning to open its own fully automated lab. Medra serves biopharmaceutical companies and research organizations, helping them design new antibodies, develop gene therapies, and run cell-based assays. The company has established collaborations with prominent partners, including Genentech, Addition Therapeutics, and Cultivarium. In December 2025, Medra announced it had raised $52 million in a Series A funding round led by Human Capital, with participation from investors such as Lux Capital, Neo, and Menlo Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
San Francisco, United States
Employees
47
Open positions
8
Dealroom signal
92.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Core AI, Woman Founder, Lab Automation, DT and LS
Technology
Artificial Intelligence, Hardware, Deep Tech, Machine Learning, Natural Language Processing, Computer Vision
Business model
Manufacturing
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2025 $52M $208M Lux Capital · Menlo Ventures · Human Capital · Fusion Fund ↗
SEEDOther financing Sep 2025 $11M $44M Nat Friedman · Patrick Hsu · Lux Capital · Neo vc ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Medra website traffic

Latest recorded traffic for Medra is 16K monthly website visits, up 14.3% over the last three months. Medra's team grew 56.7% over the past year.

Latest monthly visits16K 3-month web change+14.3% 1-year team growth+56.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

Series A6 investors entered at this stage

  • Human Capital
  • Menlo Ventures
  • Fusion Fund
  • Catalio Capital Management
  • 776 Capital
  • NFDG

Other known investors1 additional known investor

  • PharmStars
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.7%
🇸🇬 Singapore3.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Medra on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Medra’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.